GlassScriptPhysician profile
Jillian Sonkin
NPI 1639473267
$9,621.27
in general payments reported to CMS, 2019-2025
45 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,264 · 2022: $1,911 · 2023: $1,820 · 2024: $2,004 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,446.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,861.66 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $915.00 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $841.50 | 2021-2025 | |
| Lilly USA, LLC | $746.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $658.04 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $620.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $518.76 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $367.66 | 2021-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $336.77 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $291.02 | 2021-2024 | Belsomra, Steglatro, Verquvo |
| Kowa Pharmaceuticals America, INC. | $197.17 | 2021-2023 | Seglentis, Livalo |
| Esperion Therapeutics, INC. | $175.13 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $170.79 | 2021-2024 | Xarelto |
| Endo Pharmaceuticals INC. | $164.31 | 2021-2022 | |
| Amarin Pharma, INC. | $154.46 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Sonkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.